Smoldering Multiple Myeloma Clinical Trial
Official title:
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
This study is based on results from two prior studies in which 4 of 36 patients with SMM and none of 14 patients with MGUS were found to have AL. The hypothesis that we test with this protocol is that patients with (1) a pre-existing diagnosis of SMM, (2) free light chain (FLC) abnormalities, (3) IGLV genes associated with AL,(4) t(11;14) or gain 1q, and (5) NT-proBNP > 332pg/mL will have undiagnosed AL or risk of progression to AL. We will study the potential for SMM, the FLC screen, AL-related IGLV gene use, t(11;14) or gain 1q cytogenetic abnormalities, and NT-proBNP > 332pg/mL to be the variables in a likelihood algorithm for AL. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01222286 -
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
|
Phase 2 | |
| Withdrawn |
NCT00503763 -
Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT02916771 -
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01955395 -
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
|
N/A | |
| Completed |
NCT01237054 -
Imaging in MGUS, SMM and MM
|
Phase 2 | |
| Completed |
NCT02903381 -
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT03301220 -
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
|
Phase 3 | |
| Active, not recruiting |
NCT03236428 -
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01718899 -
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00112827 -
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT00099047 -
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
|
Phase 2 | |
| Terminated |
NCT01248455 -
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT03289299 -
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
|
Phase 2 | |
| Active, not recruiting |
NCT02415413 -
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01302886 -
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05841550 -
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06183489 -
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT06383143 -
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
|
||
| Active, not recruiting |
NCT02886065 -
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
|
Phase 1 | |
| Withdrawn |
NCT01571726 -
Imaging Studies and the Development of Multiple Myeloma
|
Phase 2 |